Generic Name and Formulations:
Miglustat 100mg; caps.
Indications for ZAVESCA:
Mild to moderate type 1 Gaucher disease when enzyme replacement therapy is not feasible.
≥18yrs: 100mg 3 times daily; may reduce to 100mg once or twice daily if diarrhea or tremor occurs. Mild renal impairment (CrCl 50–70mL/min): 100mg twice daily. Moderate renal impairment (CrCl 30–50mL/min): 100mg once daily. Severe renal impairment: not recommended.
<18yrs: not recommended.
Perform neurological evaluations at baseline, then periodically at 6-month intervals. Reevaluate and consider discontinuation if signs/symptoms of peripheral neuropathy develop (eg, numbness, tingling). GI disease (eg, inflammatory bowel). Use effective methods of contraception during therapy; men should maintain contraception for 3 months after treatment. Elderly. Labor & delivery. Nursing mothers: not recommended.
Glucosylceramide synthase inhibitor.
May antagonize imiglucerase.
Diarrhea, weight loss, tremor, flatulence, abdominal pain, GI disturbances, weakness, headache, dizziness, paresthesia, cramps, thrombocytopenia, reduced spermatogenesis, peripheral neuropathy.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Differences in Efficacy and Tolerability of ADHD Medications Across Age Groups
- Associations Between Hypovitaminosis D and Poorer Outcomes in Schizophrenia
- Oxycontin's Maker Now Selling Drug to Curb Opioid Addiction
- Comorbid Narcolepsy and Schizophrenia in Adolescents
- Ketamine in Electroconvulsive Therapy Accelerates Antidepressive Effects
- Quetiapine Exposure Does Not Appear to Increase Risk for Infant Malformations
- Selective Serotonin Reuptake Inhibitors May Increase Risk for Suboptimal Fetal Growth
- Transdermal Nicotine Boosts Mood and Cognitive Function in Late-Life Depression
- Ketamine Infusions Reduce Suicidal Ideation in Depression: Characterizing Different Responses
- Prenatal Insecticide Exposure in Mother May Be Linked to Risk for Autism in Children